Caranx Medical’s TAVIpilot Soft Submitted to FDA

February 3, 2025—Caranx Medical, a France-based developer of an autonomous robot for transcatheter aortic valve implantation/replacement (TAVI/TAVR), recently announced the submission to the FDA of TAVIpilot Soft, the company’s artificial intelligence (AI) software for real-time intraoperative guidance of TAVI/TAVR procedures.

Caranx plans to introduce TAVIpilot Soft to the market by the end of 2025.

According to the company, TAVIpilot Soft is an AI-driven intraoperative software that tracks real-time anatomic and instrument landmarks. It is intended to enable precise and accurate heart valve positioning and delivery in TAVI/TAVR procedures. TAVIpilot Soft is compatible with all cardiac imaging systems and will be compatible with principal transcatheter heart valves on the market, stated the company.